Swiss-based Hedera Dx bags €15M to help hospitals offer better cancer tests and treatments globally

Switzerland-based Hedera Dx, a techbio company, has raised €15M in a Series A financing round to drive advanced cancer care.

The investment was led by Vsquared Ventures, with new investor Tesi joining, along with continued support from Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.

Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, says, “Hedera Dx is addressing a critical gap in global oncology care. Hedera’s approach tackles the specific challenges of hospital in-house testing and results in more patients getting tested and more patients having access to targeted therapies.”

Dr. Rechsteiner adds, “Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within healthcare systems outside the US.”

The funding will support the company’s efforts to address structural barriers limiting patient access to targeted cancer therapies. Hedera Dx’s founders have previously led and scaled companies including Blueprint Genetics, Roche, and Molecular Health.

Modern cancer care

Hedera Dx, founded in 2021, is working to increase access to precision medicine in oncology. Its platform combines molecular diagnostics with clinical data to guide treatment decisions and support drug development.

The company has developed blood-based cancer testing solutions, known as liquid biopsies, for use in hospital laboratories in regions where centralised testing is not standard. These tests are in use across 11 European countries.

Hedera Dx’s team of over 20 employees includes professionals in genomics, clinical oncology, bioinformatics, artificial intelligence, and digital health. Additionally, the platform also analyses real-world data to support the development of oncology treatments.

Tommi Lehtonen, CEO and co-founder of Hedera Dx, says, “At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician globally. While there is a large number of personalised cancer treatments on the market, a very large part of patients still can’t access them. Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost-efficiently.”

“We’re not only improving access to advanced cancer care for patients — we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fueling the next wave of innovative cancer therapies,” adds Dr. Christian  Meisel, CMO and co-founder of Hedera Dx.

Brief about the investors

Vsquared Ventures supports entrepreneurs developing technologies aimed at addressing major global challenges. It invests in deeptech companies in areas such as space, computing, energy, robotics, manufacturing, sensing, AI, software, and tech-bio. The firm’s portfolio includes companies such as Isar Aerospace, IQM Quantum Computing, and Zama.ai, among others.

Tesi, officially Finnish Industry Investment Ltd, is a state-owned investment company that operates on a market-driven basis. It invests in VC and private equity funds, as well as directly in domestic startups, growth companies, and new industrial-scale businesses.